Trials / Recruiting
RecruitingNCT07079397
Hyaluronic Acid Filler Migration
The Integration Pattern of Non-Animal Stabilized Hyaluronic Acid (NASHA)- and Optimum Balance Technology (OBT)-Based Fillers: An Ultrasound and Magnetic Resonance Imaging (MRI) Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Erevna Innovations Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Soft tissue filler injections continue to grow in popularity as a method of facial rejuvenation, including volume restoration and contour enhancement. Many different hyaluronic acid (HA)-based fillers are available on the market and differ in terms of their physical and chemical properties, which results in families of fillers (e.g., Non-Animal Stabilized Hyaluronic Acid - NASHA vs. Optimal Balance Technology - OBT) with different tissue integration patterns. It has been proposed that the properties of fillers significantly influences their tendency to migrate. More specifically, thick fillers may be less prone to migration compared to fluid fillers. However, a detailed knowledge of facial anatomy, safer injection techniques, and careful product selection based on filler qualities may be preventive measures for filler migration. The goal of this study is to describe the short and intermediate-term product distribution/integration patterns of NASHA and OBT-based fillers, and to evaluate the evidence (if any) of filler migration from the intended site of injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Restylane Injectables | Participants will receive pan-facial treatment in at least one facial area using a Restylane NASHA product and at least one different facial area using Restylane OBT product. Participants will undergo three (3) scheduled MRI scans thoughout the duration of the study post HA injections. |
Timeline
- Start date
- 2025-12-11
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-07-23
- Last updated
- 2026-01-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT07079397. Inclusion in this directory is not an endorsement.